0001104659-24-003741.txt : 20240112
0001104659-24-003741.hdr.sgml : 20240112
20240112170024
ACCESSION NUMBER: 0001104659-24-003741
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240110
FILED AS OF DATE: 20240112
DATE AS OF CHANGE: 20240112
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Martin Tami Tillotson
CENTRAL INDEX KEY: 0001539494
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35518
FILM NUMBER: 24532679
MAIL ADDRESS:
STREET 1: C/O SUPERNUS PHARMACEUTICALS, INC.
STREET 2: 9715 KEY WEST AVENUE
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: SUPERNUS PHARMACEUTICALS, INC.
CENTRAL INDEX KEY: 0001356576
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 9715 KEY WEST AVENUE
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
BUSINESS PHONE: 301-838-2500
MAIL ADDRESS:
STREET 1: 9715 KEY WEST AVENUE
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
FORMER COMPANY:
FORMER CONFORMED NAME: SUPERNUS PHARMACEUTICALS INC
DATE OF NAME CHANGE: 20060317
4
1
tm243247-1_4seq1.xml
OWNERSHIP DOCUMENT
X0508
4
2024-01-10
0
0001356576
SUPERNUS PHARMACEUTICALS, INC.
SUPN
0001539494
Martin Tami Tillotson
C/O SUPERNUS PHARMACEUTICALS, INC.,
9715 KEY WEST AVENUE
ROCKVILLE
MD
20850
0
1
0
0
Sr. V.P., Regulatory Affairs
1
Common Stock
2024-01-10
4
M
0
8000
9.24
A
93664
D
Common Stock
2024-01-10
4
S
0
8000
27.91
D
85664
D
Employee Stock Option (Right to Buy)
9.24
2024-01-10
4
M
0
8000
0
D
2024-01-21
Common Stock
8000
0
D
The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023.
Includes an aggregate of 415 shares acquired by the Reporting Person through the Issuer's Employee Stock Purchase Plan.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.69 to $28.22, inclusive. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
The option vested in four equal annual installments beginning on January 21, 2015.
/s/ Timothy C. Dec, as attorney-in-fact
2024-01-12